Literature DB >> 6207311

Three major glycoprotein genes of varicella-zoster virus whose products have neutralization epitopes.

P M Keller, B J Neff, R W Ellis.   

Abstract

Varicella-zoster virus (VZV) codes for approximately eight glycosylated polypeptides in infected cell cultures and in virions. To determine the number of serologically distinct glycoprotein gene products encoded by VZV, we have developed murine monoclonal antibodies to purified virions. Of 10 monoclonal antibodies which can immunoprecipitate intracellular VZV antigens and virion glycoproteins, 1 (termed gA) reacted with gp105, 1 (termed gB) reacted with gp115 (intracellular only), gp62, and gp57, and 8 (termed gC) reacted with gp92, gp83, gp52, and gp45. The anti-gA monoclonal antibody neutralized VZV infectivity in the absence of complement. All eight anti-gC monoclonal antibodies neutralized only in the presence of complement. An anti-gB monoclonal antibody obtained from another laboratory also neutralizes in the absence of complement. Since the above reactivities account for all major detectable VZV glycoprotein species, the data strongly suggest that VZV has three major glycoprotein genes which encode glycosylated polypeptides with neutralization epitopes.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6207311      PMCID: PMC254520     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  30 in total

1.  The proteins of varicella-zoster-virus.

Authors:  M H Wolff
Journal:  Med Microbiol Immunol       Date:  1978-11-17       Impact factor: 3.402

2.  Serologic response to varicella-zoster membrane antigens measured by direct immunofluorescence.

Authors:  V Williams; A Gershon; P A Brunell
Journal:  J Infect Dis       Date:  1974-12       Impact factor: 5.226

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  Immune response after exposure to varicella zoster virus: characterization of virus-specific antibodies and their corresponding antigens.

Authors:  H J Zweerink; B J Neff
Journal:  Infect Immun       Date:  1981-01       Impact factor: 3.441

5.  Isolation and polypeptide characterization of varicella-zoster virus.

Authors:  Y Shemer; S Leventon-Kriss; I Sarov
Journal:  Virology       Date:  1980-10-15       Impact factor: 3.616

6.  Clinical and laboratory studies of KMcC strain live attenuated varicella virus.

Authors:  B J Neff; R E Weibel; V M Villarejos; E B Buynak; A A McLean; D H Morton; B S Wolanski; M R Hilleman
Journal:  Proc Soc Exp Biol Med       Date:  1981-03

7.  The synthesis of glycoproteins in human melanoma cells infected with varicella-zoster virus.

Authors:  C Grose
Journal:  Virology       Date:  1980-02       Impact factor: 3.616

8.  Characterization of an immune complex kinase in immunoprecipitates of avian sarcoma virus-transformed fibroblasts.

Authors:  N D Richert; P J Davies; G Jay; I H Pastan
Journal:  J Virol       Date:  1979-09       Impact factor: 5.103

9.  Antibody to Varicella-Zoster virus in parturient women and their offspring during the first year of life.

Authors:  A A Gershon; R Raker; S Steinberg; B Topf-Olstein; L M Drusin
Journal:  Pediatrics       Date:  1976-11       Impact factor: 7.124

10.  Type-common and type-specific monoclonal antibody to herpes simplex virus type 1.

Authors:  L Pereira; T Klassen; J R Baringer
Journal:  Infect Immun       Date:  1980-08       Impact factor: 3.441

View more
  26 in total

1.  Bovine herpesvirus type 1 gp87 mediates both attachment of virions to susceptible cells and hemagglutination.

Authors:  K Okazaki; E Honda; T Minetoma; T Kumagai
Journal:  Arch Virol       Date:  1987       Impact factor: 2.574

2.  Neutralizing antibodies specific for glycoprotein H of herpes simplex virus permit viral attachment to cells but prevent penetration.

Authors:  A O Fuller; R E Santos; P G Spear
Journal:  J Virol       Date:  1989-08       Impact factor: 5.103

3.  Cross-reactivity between herpes simplex virus glycoprotein B and a 63,000-dalton varicella-zoster virus envelope glycoprotein.

Authors:  C M Edson; B A Hosler; R A Respess; D J Waters; D A Thorley-Lawson
Journal:  J Virol       Date:  1985-10       Impact factor: 5.103

4.  Transcription mapping of the varicella-zoster virus genome.

Authors:  J M Ostrove; W Reinhold; C M Fan; S Zorn; J Hay; S E Straus
Journal:  J Virol       Date:  1985-11       Impact factor: 5.103

5.  High-level cellular and humoral immune responses in Guinea pigs immunized intradermally with a heat-inactivated varicella-zoster virus vaccine.

Authors:  Julia Sarkadi; Mate Jankovics; Kinga Fodor; Zoltan Kis; Maria Takacs; Ildiko Visontai; Istvan Jankovics; Eva Gonczol
Journal:  Clin Vaccine Immunol       Date:  2015-03-18

6.  Identification of a neutralizing epitope on glycoprotein gp58 of human cytomegalovirus.

Authors:  U Utz; W Britt; L Vugler; M Mach
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

7.  Characterization of neutralizing epitopes of varicella-zoster virus glycoprotein H.

Authors:  Yasushi Akahori; Kazuhiro Suzuki; Tohru Daikoku; Masae Iwai; Yoshihiro Yoshida; Yoshizo Asano; Yoshikazu Kurosawa; Kimiyasu Shiraki
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

8.  Insulin degrading enzyme induces a conformational change in varicella-zoster virus gE, and enhances virus infectivity and stability.

Authors:  Qingxue Li; Mir A Ali; Kening Wang; Dean Sayre; Frederick G Hamel; Elizabeth R Fischer; Robert G Bennett; Jeffrey I Cohen
Journal:  PLoS One       Date:  2010-06-25       Impact factor: 3.240

9.  Intracellular transport of newly synthesized varicella-zoster virus: final envelopment in the trans-Golgi network.

Authors:  A A Gershon; D L Sherman; Z Zhu; C A Gabel; R T Ambron; M D Gershon
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

10.  Neutralizing antibodies induced by recombinant vaccinia virus expressing varicella-zoster virus gpIV.

Authors:  A Vafai; W N Yang
Journal:  J Virol       Date:  1991-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.